BLS Pharmaceuticals targets $105M–$115M revenue for FY2027

BLS Pharmaceuticals Limited (ASX: BLS) has announced revenue guidance for fiscal year 2027, targeting between $105 million and $115 million. This represents a projected growth of 42% to 55% compared to its FY2026 revenue of $74.2 million. The company also provided an Adjusted EBITDA margin guidance of 23% to 26% for the same period.

The Australian pharmaceutical company, which specializes in regulated therapeutic products including medicinal cannabis and psychedelic medicines, attributes this outlook to several strategic factors. These include strong domestic demand in Australia and the execution of international contracts, such as a two-year A$50 million supply agreement with Germany-based ADREXpharma.

To support international expansion, BLS is constructing a new GMP production site in the Scottish Borders, United Kingdom, which is expected to be completed by the end of 2026. The company has also secured manufacturing agreements with industry leaders Aurora Cannabis and Curaleaf International, and maintains commercial relationships across Europe and Latin America.